Table 2.
Continuous methylation-derived neutrophil-to-lymphocyte ratio and lung cancer risk overall and by sex, asbestos exposure, smoking status, intervention arm, and median time at risk.
| Alla lung cancers | Non-small cell lung cancer |
Small cell lung cancer |
||||
|---|---|---|---|---|---|---|
| ORb | (95% CI) | ORb | (95% CI) | ORb | (95% CI) | |
| Continuous mdNLR | 1.21 | (1.01, 1.44) | 1.30 | (1.03, 1.63) | 1.06 | (0.77, 1.47) |
| Sex | ||||||
| Male | 1.30 | (1.04, 1.63) | 1.34 | (1.02, 1.75) | 1.24 | (0.79, 1.93) |
| Female | 1.05 | (0.76, 1.45) | 1.22 | (0.75, 1.98) | 0.94 | (0.53, 1.66) |
| Asbestos exposure | ||||||
| Yes | 2.13 | (1.12, 4.05) | 3.39 | (1.32, 8.67) | 1.27 | (0.54, 2.95) |
| No | 1.09 | (0.90, 1.32) | 1.15 | (0.92, 1.45) | 0.96 | (0.61, 1.52) |
| Smoking status | ||||||
| Never/former | 1.26 | (0.98, 1.63) | 1.24 | (0.92, 1.68) | 1.52 | (0.80, 2.90) |
| Current | 1.16 | (0.91, 1.47) | 1.40 | (0.98, 2.00) | 0.76 | (0.44, 1.34) |
| Stage | ||||||
| Early (I/II) | 1.30 | (0.79, 2.13) | 1.29 | (0.79, 2.12) | -- | -- |
| Late (III/IV) | 1.35 | (1.08, 1.70) | 1.44 | (1.08, 1.92) | 1.19 | (0.81, 1.74) |
| Intervention arm | ||||||
| Placebo | 1.11 | (0.78, 1.59) | 1.32 | (0.86, 2.02) | 0.70 | (0.26, 1.87) |
| Active | 1.70 | (1.12, 2.58) | 1.53 | (0.89, 2.62) | 2.47 | (0.79, 7.73) |
| Time at risk (median in cases = 4.4 years) | ||||||
| <4.4 years | 1.25 | (0.99, 1.58) | 1.34 | (0.99, 1.80) | 1.20 | (0.81, 1.76) |
| ≥4.4 years | 1.18 | (0.89, 1.57) | 1.27 | (0.88, 1.84) | 0.80 | (0.37, 1.71) |
Abbreviations: OR = odds ratio; CI = confidence interval; mdNLR = methylation-derived neutrophil-to-lymphocyte ratio; BMI = body mass index.
a
”All lung cancers” includes non-small cell lung cancer pairs (N=240) and small cell lung cancer pairs (N=68), as well as pairs for whom case histotype was missing (N=11).
b
Conditional logistic regression models adjusted for age, pack years, cigarettes per day, and BMI at blood draw.
Bold OR and CI indicate statistical significance.